ArticleCureus2025
An Unusual Case of Psoriatic Arthritis With Peliosis Hepatis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peliosis hepatis is a rare condition characterized by dilation of the hepatic sinusoids and the presence of multiple blood-filled cystic spaces within the liver parenchyma. It has been associated with a variety of etiologies, including infectious diseases, immunological disorders, malignancy, and certain medications. We report a case of a 24-year-old male who presented with polyarthritis lasting two months. His medical history revealed a family and personal history of psoriasis, with no known drug use. The physical examination revealed psoriatic lesions localized to specific areas, accompanied by synovitis in his elbows, wrists, ankles, and knees. Biological tests showed elevated gamma-glutamyl transferase (298 IU/L, normal range: 12-64 IU/L) and total alkaline phosphatase (341 IU/L, normal range: 11-55 IU/L), while hepatitis A, B, and C serologies were negative. Additionally, a broad panel of autoimmune antibodies (including anti-nuclear, anti-Ro/SSA, anti-M2, anti-SP100, anti-SLA, and anti-LKM1) were all negative. The abdominal Doppler ultrasound and liver MRI with gadolinium contrast have shown homogeneous hepatosplenomegaly. A liver biopsy revealed features consistent with peliosis hepatis. Imaging studies revealed sacroiliac sclerosis, leading to a diagnosis of psoriatic arthritis complicated by peliosis hepatis. The patient initially received secukinumab (300 mg monthly), with partial improvement, followed by a switch to etanercept, which resulted in a significant clinical and biochemical response over six months. This case highlights the importance of considering peliosis hepatis in patients with psoriatic arthritis who present with liver enzyme abnormalities. It also demonstrates the safety and efficacy of anti-tumor necrosis factor (TNF) agents, particularly etanercept, in managing this condition compared to anti-IL17 therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.